Androgen deprivation therapy use and risk of mild cognitive impairment in prostate cancer patients

Hector Alonso-Quiñones, Bradley J. Stish, Jeremiah A. Aakre, Clinton E. Hagen, Ronald C. Petersen, Michelle M. Mielke

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction:We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients.Methods:We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score.Results:There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27).Conclusion:ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.

Original languageEnglish (US)
Pages (from-to)44-47
Number of pages4
JournalAlzheimer disease and associated disorders
Volume35
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Cognition
  • Longitudinal study
  • Prostate cancer

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Androgen deprivation therapy use and risk of mild cognitive impairment in prostate cancer patients'. Together they form a unique fingerprint.

Cite this